{"product_id":"proteogenix-gevokizumab-biosimilar-anti-il1b-mab-research-grade","title":"Gevokizumab Biosimilar – Anti-IL1B mAb – Research Grade","description":"\u003ch3\u003eIntroduction\u003c\/h3\u003e \u003cp\u003eGevokizumab Biosimilar, also known as Anti-IL1B mAb, is a research grade monoclonal antibody that targets the cytokine interleukin-1 beta (IL-1B). This antibody has shown promising results in clinical trials for the treatment of inflammatory diseases and is currently being developed as a biosimilar to the original drug, gevokizumab.\u003c\/p\u003e \u003ch3\u003eStructure of Gevokizumab Biosimilar\u003c\/h3\u003e \u003cp\u003eGevokizumab Biosimilar is a humanized monoclonal antibody, meaning it is derived from both human and mouse sources. It consists of two identical heavy chains and two identical light chains, each with a molecular weight of approximately 150 kDa. These chains are linked by disulfide bonds and form a Y-shaped structure.\u003c\/p\u003e \u003cp\u003eThe variable regions of the antibody, located at the tips of the Y, are responsible for binding to IL-1B. The constant regions, located at the base of the Y, are responsible for mediating effector functions such as antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC).\u003c\/p\u003e \u003ch3\u003eMechanism of Action\u003c\/h3\u003e \u003cp\u003eIL-1B is a pro-inflammatory cytokine that plays a key role in the pathogenesis of many diseases, including rheumatoid arthritis, gout, and type 2 diabetes. Gevokizumab Biosimilar works by binding to IL-1B and preventing it from interacting with its receptors on target cells.\u003c\/p\u003e \u003cp\u003eBy blocking the activity of IL-1B, Gevokizumab Biosimilar reduces inflammation and associated symptoms such as pain and swelling. It also helps to regulate the immune response and promote tissue repair.\u003c\/p\u003e \u003ch3\u003eApplications of Gevokizumab Biosimilar\u003c\/h3\u003e \u003cp\u003eGevokizumab Biosimilar has shown promising results in clinical trials for the treatment of various inflammatory diseases. It has been studied in patients with rheumatoid arthritis, psoriasis, and gout, among others.\u003c\/p\u003e \u003cp\u003eOne of the key advantages of this biosimilar is its potential to offer a more cost-effective alternative to the original drug, gevokizumab. This could make it more accessible to patients in need of treatment for these debilitating diseases.\u003c\/p\u003e \u003ch3\u003eResearch Grade vs. Therapeutic Grade\u003c\/h3\u003e \u003cp\u003eGevokizumab Biosimilar is currently being developed as a research grade antibody, meaning it is intended for use in laboratory research and not for human therapeutic purposes. However, it is important to note that the same antibody can be used for both research and therapeutic purposes, as long as it meets the necessary quality and safety standards.\u003c\/p\u003e \u003cp\u003eIn order for Gevokizumab Biosimilar to be approved for therapeutic use, it will need to undergo further clinical trials and meet stringent regulatory requirements. This process can take several years, but if successful, the biosimilar could potentially provide a more affordable treatment option for patients.\u003c\/p\u003e \u003ch3\u003eConclusion\u003c\/h3\u003e \u003cp\u003eGevokizumab Biosimilar, also known as Anti-IL1B mAb, is a research grade monoclonal antibody that targets the pro-inflammatory cytokine IL-1B. It has shown promising results in clinical trials for the treatment of inflammatory diseases and is being developed as a biosimilar to the original drug, gevokizumab. Its unique structure and mechanism of action make it a promising candidate for the treatment of various inflammatory conditions. Further research and development will be necessary before it can be approved for therapeutic use, but if successful, it could offer a more cost-effective treatment option for patients in need.\u003c\/p\u003e\u003cp\u003eProteoGenix catalogue number PX-TA1068. For research use only.\u003c\/p\u003e\u003cp\u003eTarget: Gevokizumab Biosimilar – Anti-IL1B mAb – Research Grade; Clonality: Monoclonal Antibody; Expression system: Mammalian cells; Purity: \u0026gt;85%; Molecular weight: 145kDa; Buffer: PBS buffer PH7.5; Applications: ELISA, WB.\u003c\/p\u003e\u003cp\u003eAvailable configurations: 50ug, 100ug, 1mg.\u003c\/p\u003e\u003cp\u003e\u003ca href=\"https:\/\/www.proteogenix.science\/wp-content\/uploads\/documents\/Datasheets\/PX-TA1068.pdf\"\u003eDownload the manufacturer datasheet\u003c\/a\u003e\u003c\/p\u003e\u003cp\u003e\u003ca href=\"https:\/\/www.proteogenix.science\/wp-content\/uploads\/documents\/msds\/MSDS_PX-TA1068.pdf\"\u003eDownload the manufacturer safety data sheet (MSDS\/SDS)\u003c\/a\u003e\u003c\/p\u003e","brand":"ProteoGenix","offers":[{"title":"50ug","offer_id":57357949632852,"sku":"ABM134966-1","price":108.0,"currency_code":"GBP","in_stock":true},{"title":"100ug","offer_id":57357949665620,"sku":"ABM134966-2","price":175.2,"currency_code":"GBP","in_stock":true},{"title":"1mg","offer_id":57357949698388,"sku":"ABM134966-3","price":367.2,"currency_code":"GBP","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1040\/1782\/2036\/files\/bioactivity-validation-gevokizumab-biosimilar-anti-il1b-mab-research-grade_6a717693-6e8a-4806-951d-d82de74d7e1b.jpg?v=1790891397","url":"https:\/\/www.abmium.com\/es\/products\/proteogenix-gevokizumab-biosimilar-anti-il1b-mab-research-grade","provider":"ABMIUM","version":"1.0","type":"link"}